Lurbinectedin
- Generic Name
- Lurbinectedin
- Brand Names
- Zepzelca, 赞必佳
- Drug Type
- Small Molecule
- Chemical Formula
- C41H44N4O10S
- CAS Number
- 497871-47-3
- Unique Ingredient Identifier
- 2CN60TN6ZS
- Background
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate Ecteinascid...
- Indication
Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- Associated Conditions
- Metastatic Lung Small Cell Carcinoma
- Associated Therapies
- -
Biomarker Directed Trial of Temozolomide and PARP Inhibition in Relapsed SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 152
- Registration Number
- NCT06681220
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois, United States
An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Target Recruit Count
- 9
- Registration Number
- NCT06501976
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06496048
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 30
- Registration Number
- NCT06497530
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 15
- Registration Number
- NCT06385548
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
- Conditions
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT06228066
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 70
- Registration Number
- NCT06217536
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 540
- Registration Number
- NCT06203210
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
Study of Lurbinectedin in Combination with Doxorubicin Versus Doxorubicin Alone As First-line Treatment in Participants with Metastatic Leiomyosarcoma
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 360
- Registration Number
- NCT06088290
- Locations
- 🇺🇸
Vanderbilt - Ingram Cancer Center, Nashville, Tennessee, United States
🇫🇷Centre Hospitalier Régional et Universitaire de Besançon - Hôpital Jean-Minjoz, Besançon Cedex, Doubs, France
🇮🇹Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Istituto Clinico Humanitas, Rozzano, Milan, Italy
Lurbinectedin in FET-Fused Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 56
- Registration Number
- NCT05918640
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.